The Effect of Benralizumab on Inflammation in Severe Asthma: a Real-life Analysis

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2024 Dec 17

PMID 39686520

Authors

Dina Visca

Francesco Ardesi

Martina Zappa

Sarah Grossi

Patrizia Pignatti

Marco Vanetti

Laura Pini

Giovanni Sotgiu

Rosella Centis

Giovanni Battista Migliori

Antonio Spanevello

Affiliations

Soon will be listed here.

Abstract

Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.

Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.

Design: This is a retrospective observational study, in an Italian tertiary reference centre specialised in diagnosis and management of severe asthma patients.

Methods: We conducted a monocentric retrospective study including SEA patients treated with benralizumab for 1 year. Clinical, functional and inflammatory data were collected at baseline, 6 (T6) and 12 (T12) months.

Results: Twenty-two SEA patients on benralizumab were included. We observed a reduction in exacerbations rate and systemic steroid treatment ( < 0.0001) as well as an improvement in asthma control ( < 0.0001), health-related quality of life ( = 0.017) and lung function pre-BD FEV1 (L) ( = 0.02) and percentage ( = 0.004) and post-BD FEV1 (L) ( = 0.01) and percentage ( = 0.003) from baseline to T6 and T12. A reduction in sputum eosinophil percentage was observed at T6 and T12 ( < 0.005). We found a positive correlation between the variation of sputum eosinophils percentage and FEV1 (L) at T12 (rho = -0.79, = 0.04). Moreover, the improvement of FEF from baseline to 6 (rho = -0.53, = 0.03) and 12 (rho = -0.62, = 0.01) months negatively correlated with the duration of asthma disease.In our cohort 12/22 patients were super-responders at T6 and 15/22 at T12. Furthermore, clinical remission was reached by 12/22, and all of them obtained blood and sputum eosinophils counts normalisation.

Conclusion: Our data confirm that it is a rapid and effective treatment for SEA acting on clinical, functional, systemic and airway inflammatory outcomes. Our results highlight the role of induced sputum as a promising non-invasive technique to investigate pathophysiologic mechanisms in severe asthma treated with biologics. Finally, a negative correlation between small airway improvement and the duration of asthma may suggest that a prompt referral to asthma centres may delay lung function worsening. Additional studies are needed to investigate more in-depth the role of induced sputum in the management of asthma, response to treatment and remission.

References

Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica G . Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2020; 10:1514. PMC: 6927944. DOI: 10.3389/fphys.2019.01514. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624):806-8. PMC: 2034723. DOI: 10.1136/bmj.39335.541782.AD. View

Juniper E, OByrne P, Guyatt G, Ferrie P, King D . Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14(4):902-7. DOI: 10.1034/j.1399-3003.1999.14d29.x. View

Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C . Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014; 108(12):1723-32. DOI: 10.1016/j.rmed.2014.10.007. View

Graff S, Bricmont N, Moermans C, Henket M, Paulus V, Guissard F . Clinical and biological factors associated with irreversible airway obstruction in adult asthma. Respir Med. 2020; 175:106202. DOI: 10.1016/j.rmed.2020.106202. View

Harrison T, Chanez P, Menzella F, Canonica G, Louis R, Cosio B . Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2020; 9(3):260-274. DOI: 10.1016/S2213-2600(20)30414-8. View

Wecker H, Tizek L, Ziehfreund S, Kain A, Traidl-Hoffmann C, Zimmermann G . Impact of asthma in Europe: A comparison of web search data in 21 European countries. World Allergy Organ J. 2023; 16(8):100805. PMC: 10410582. DOI: 10.1016/j.waojou.2023.100805. View

Gerday S, Graff S, Moermans C, Guissard F, Paulus V, Henket M . Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline. Thorax. 2023; 78(11):1138-1141. PMC: 10715510. DOI: 10.1136/thorax-2022-219781. View

Laviolette M, Gossage D, Gauvreau G, Leigh R, Olivenstein R, Katial R . Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013; 132(5):1086-1096.e5. PMC: 4172321. DOI: 10.1016/j.jaci.2013.05.020. View

10.

Nathan R, Sorkness C, Kosinski M, Schatz M, Li J, Marcus P . Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004; 113(1):59-65. DOI: 10.1016/j.jaci.2003.09.008. View

11.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

12.

Menzella F, Fontana M, Galeone C, Ghidoni G, Capobelli S, Ruggiero P . Real world effectiveness of benralizumab on respiratory function and asthma control. Multidiscip Respir Med. 2021; 16(1):785. PMC: 8506201. DOI: 10.4081/mrm.2021.785. View

13.

Tsubokawa F, Koya T, Murai Y, Tanaka K, Tsutsui Y, Naramoto S . Effects of Benralizumab on Three-Dimensional Computed Tomography Analysis in Severe Eosinophilic Asthma. Int Arch Allergy Immunol. 2022; 184(3):243-251. DOI: 10.1159/000525846. View

14.

Ten Brinke A, Zwinderman A, Sterk P, Rabe K, Bel E . Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001; 164(5):744-8. DOI: 10.1164/ajrccm.164.5.2011026. View

15.

Pelaia C, Busceti M, Crimi C, Carpagnano G, Lombardo N, Terracciano R . Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020; 129:110444. DOI: 10.1016/j.biopha.2020.110444. View

16.

Miralles-Lopez J, Andujar-Espinosa R, Bravo-Gutierrez F, Castilla-Martinez M, Flores-Martin I, Alemany-Frances M . Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol Immunopathol (Madr). 2022; 50(6):163-168. DOI: 10.15586/aei.v50i6.704. View

17.

Fanta C . Clinical aspects of mucus and mucous plugging in asthma. J Asthma. 1985; 22(6):295-301. DOI: 10.3109/02770908509087113. View

18.

Nolasco S, Crimi C, Pelaia C, Benfante A, Caiaffa M, Calabrese C . Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. J Allergy Clin Immunol Pract. 2021; 9(12):4371-4380.e4. DOI: 10.1016/j.jaip.2021.08.004. View

19.

Kavanagh J, Hearn A, Dhariwal J, dAncona G, Douiri A, Roxas C . Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2020; 159(2):496-506. DOI: 10.1016/j.chest.2020.08.2083. View

20.

Pham T, Damera G, Newbold P, Ranade K . Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016; 111:21-9. DOI: 10.1016/j.rmed.2016.01.003. View